Article

Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapy

2026-06-18

Abstract excerpt

<title>Abstract</title> <p> <bold>Introduction and background</bold> Systemic therapy remains standard-of-care for stage IV lung cancer patients, with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) having improved outcomes. However, in metastatic lung cancer 5-year overall survival (OS) remains poor. Moreover, frail and comorbid patients often experience more side effects and require more interventions...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f44e0f7-0e31-5b9d-bf57-102d510eab3a
DOI: 10.21203/rs.3.rs-9429129/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapyDOI 10.21203/rs.3.rs-9429129/v1Read

Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity Read

Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity Read

Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity Read

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read

Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity Read

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read

The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.Semantic proximity Read

Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity Read

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.Semantic proximity Read

[Targeted therapies for non-small cell lung cancer : state of the art in 2021].Semantic proximity Read

A Qualitative Research Exploring the Experiences of Patients Receiving Immune Checkpoint Inhibitors for Advanced Lung CancerSemantic proximity Read

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.Semantic proximity Read